Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma

Key facts

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Principal Investigator

Yutian Chong, MD, M.D

Third Affiliated Hospital, Sun Yat-Sen University

Intervention

Vitamin D3(drug)

Enrollment

1500 target

Eligibility

18-70 years · All sexes

Timeline

2016 – 2026

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hepatitis delta

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT07454837
  Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
  Mirum Pharmaceuticals, Inc.
• RECRUITINGNCT07491848
  Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
  Research Center of Periodontal-Systemic Interactions
• RECRUITINGPHASE3NCT07298330
  A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
  Mirum Pharmaceuticals, Inc.
• RECRUITINGNCT07317011
  "Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.
  FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
• RECRUITINGNCT07429864
  Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
  Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• RECRUITINGPHASE3NCT07200908
  A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
  Mirum Pharmaceuticals, Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT07142811
  A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
  Vir Biotechnology, Inc.
• RECRUITINGPHASE1, PHASE2NCT07096193
  Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
  Gilead Sciences

See all trials for Hepatitis delta →